Press Releases

An open letter sent to the UK and EU heads of state, and European Commission leadership urging for immediate provision of COVID-19 vaccines to all migrants residing in the UK and EU. More

Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convened a virtual policy dialogue to share how COVID-19 has impacted global hepatitis C elimination efforts. More

Advocates scandalized that Gilead’s hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billion in profits. More

European Patent Office (EPO) has taken its decision following Médecins du Monde (MdM) patent opposition on Gilead’s sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent. More

People with HCV and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. More

On the eve of Gilead’s annual shareholder meeting, thousands of activists have demanded that Gilead change its policies that deny access to treatment for millions in developing countries. More

Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C drug. More

The World Health Assembly passed new Hepatitis Resolution committing WHO and UN member states to urgent action to address the global hepatitis pandemic. More

As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in LMICs. More

Activists from 22 countries joined forces at the first-ever HCV World CAB to demand equitable access to HCV treatment from six multinational pharmaceutical companies. More